HCoV-229E-IN-1-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEHCoV-229E-IN-1Cat.No.:HY-132169分?式:C??H??N?O?分?量:583.85作?靶點(diǎn):SARS-CoV作?通路:Anti-infection儲(chǔ)存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:12.5mg/mL(21.41mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM1.7128mL8.5638mL17.1277mL5mM0.3426mL1.7128mL3.4255mL10mM0.1713mL0.8564mL1.7128mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:1.67mg/mL(2.86mM);Suspendedsolution;Needultrasonic2.請(qǐng)依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥1.25mg/mL(2.14mM);Clearsolution1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE3.請(qǐng)依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥1.25mg/mL(2.14mM);ClearsolutionBIOLOGICALACTIVITY?物活性HCoV-229E-IN-1HCoV-229E復(fù)制的有效抑制劑，在MTS和CPE細(xì)胞中的EC50值分別為0.65μM和0.6μM。IC50&TargetIC50:0.65μM(HCoV-229E)[1]體外研究HCoV-229E-IN-1(compound5h)(0.01-100μM)fullysuppressesthecapacityofHCoV-229Ereplicationinadose-dependentmanner[1].HCoV-229E-IN-1(12μM)fullypreventedtheformationofdsRNAintermediatesofCoVRNAsynthesis[1].REFERENCES[1].StevaertA,et,al.BetulonicAcidDerivativesInterferingwithHumanCoronavirus229EReplicationviathensp15Endoribonuclease.JMedChem.2021May13;64(9):5632-5644.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:400-820-3792;